The Windsor Cancer Research Group was initiated by the University of Windsor and Windsor Regional Hospital to bring together local researchers and healthcare professionals to strengthen our local cancer research programs and bridge collaborations with our neighbouring cancer centres.
Already, WCRG is coming together as teams to focus our efforts in some specific areas of cancer research:
- Breast Cancer Research
- Prostate Cancer Research
- Blood Cancer Research
- Brain Cancer Research
- Innovative Clinical Trials
- Psych-social Cancer Research
- International partnerships
Here are some of the collaborative research projects that are going on in our community.
Dora Cavallo-Medved and Lisa Porter
“Caveolin-1 mediates proteolysis and invasion in the tumour microenvironment of prostate cancer”
We are investigating the role of caveolin-1 within the prostate tumour microenvironment as a mediator of proteolysis and tumour invasion.
Michael Boffa, Dora-Cavallo-Medved and Lisa Porter
“Is TAFI1 a novel anti-metastatic factor in breast cancer?”
We are determining whether the activation of TAFI in the breast microenvironment reduces tumor invasion and angiogenesis.
Tarek Elfeki, Kalid Hirmiz, Caroline Hamm and Maher El-Masri
“Exploring the independent predictors of 5-year survival in patients with colorectal cancer”
This retrospective chart review investigates the influence of different therapeutic approaches, diagnostics, demographics and prognostic factors on the 5-year survival of patients with colorectal cancer.
Caroline Hamm and Lisa Porter
“Correlation of Spy-1 levels in patients during a phase II trial of patients with triple negative breast cancer receiving carboplatin with dose dense adriamycin/cyclophosphamide/taxol in combination with carboplatin”
Women with “triple negative breast cancer” are 15% more likely to die from their cancer and we are determining if an altered chemotherapy protocol will change this statistic.
Caroline Hamm and Maher El-Masri
“Comparing survival between women with triple negative breast cancer (TNBC) and women with non-TNBC; and exploring the factors associated with survival in women with TNBC”
TNBC is thought to be more aggressive among younger women and our research is suggesting that this is confounded by type of treatment and stage and grade of cancer at diagnosis.
John Hudson, Caroline Hamm and Sindu Kanjeekal
“Regulation of the expression of Plks in myelodysplastic syndromes (MDS) and hematological malignancies”
Our project’s goal is to advance our understanding of hematological malignancies in the context of the Plks with the hope of translating these discoveries to better patient outcomes.
Bulent Mutus and Lisa Porter
“Inhibition of neutral sphingomyelinase 2 can lead to breast cancer cell survival through plasma membrane steroid receptor destabilization on cholesterol rafts”
The findings from this research may contribute to novel therapeutic strategies to improve the treatment and/or the detection of aggressive forms of breast cancer.
Siyaram Pandey and Caroline Hamm
“Preclinical evaluation of anti-cancer activity of Dandelion root extract (DRE) in in vitro, in vivo and ex-vivo models of leukemia”
Results obtained from this research project will present a new window of opportunity for the treatment of some of the most aggressive and chemo-resistant leukemia by a plant extract.
Lisa Porter, Dora Cavallo-Medved and Caroline Hamm
“Role of the novel cell cycle regulator Spy1 in hematopoetic self-renewal; implications in multiple myeloma.
This study will determine how to better design CDK inhibitors to effectively treat patients with relapsed multiple myeloma.